GenprexNASDAQ: GNPX

Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a stockholder letter and corporate update summarizing the Company's recent achievements across its clinical development programs and outlines key milestones for 2024 and beyond. "Genprex continues to make progress across a number of areas critical to advancing our novel gene therapies in oncology and diabetes," said Ryan Confer, President and Chief Executive Officer.

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention. Event: 2024 BIO International Convention Conference Dates: June 3-6, 2024 Presentation Date: Monday, June 3, 2024 Presentation Time: 2:00 p.m.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company specializing in developing transformative treatments for cancer and diabetes, revealed its involvement in several investor and industry conferences scheduled for May 2024 in Austin, Texas.

Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.

GENPREX (GNPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Genprex Inc. revealed that the China National Intellectual Property Administration has granted it a broad patent, which covers the use of its lead drug candidate REQORSA Immunogene therapy, in combination with PD1 antibodies through 2037, to treat cancers.

Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its therapeutic REQORSA in combination with Genentech's Tecentriq in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as an initial standard treatment. The company has previously received two other FTDs for its therapeutic: one for REQORSA in combination with AstraZeneca's Tagrisso in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso, and one for REQORSA in combination with Merck & Co's Keytruda in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda.

Genprex's (GNPX) shares rise due to the advancement of early-stage Acclaim-1 study for patients with late-stage non-small cell lung cancer.

Genprex Inc. revealed that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial evaluating REQORSA Immunogene therapy combined with Tagrisso in late-stage non-small cell lung cancer (NSCLC), and the Safety Review Committee (SRC) has approved forging ahead with the Phase 2 expansion part of the trial.